On this episode of BioTalk, Geoff Meyerson, CEO of Locust Walk, sits down with David Harel, CEO and Co-founder of CytoReason. CytoReason uses AI-powered disease models to transform drug discovery and development, offering pharmaceutical companies insights that reduce both time and costs in bringing new therapies to market.

David shares his journey from private equity to co-founding CytoReason—an idea sparked on a beach in Israel. They discuss why no one had applied molecular data this way before, how CytoReason’s models differ from existing approaches, and the benefits they offer in accelerating drug development. They also delve into the evolving role of AI in drug discovery, the transformative potential it holds, and the critical challenges the industry will face as the field scales. 

Reflecting on the importance of diverse thinking in this fast-evolving space, David notes,

"Diversity of opinions is critical to making things work. You need diverse perspectives to distill the truth before it's delivered to the customer, who is highly educated and smart. Without tough questions being asked openly, things can fall apart quickly."

David also offers three key pieces of advice for entrepreneurs looking to enter the intersection of AI and life sciences today.

Subscribe or follow Biotalk on Apple Podcasts | Spotify.